U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Tue Apr 01 16:34:18 GMT 2025
Edited
by admin
on Tue Apr 01 16:34:18 GMT 2025
Protein Type RECEPTOR
Protein Sub Type GROWTH FACTOR RECEPTOR
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
RO03J093CP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EGFR
Preferred Name English
EPIDERMAL GROWTH FACTOR RECEPTOR
Common Name English
ERBB
Common Name English
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1
Common Name English
HER1
Common Name English
HER-1
Common Name English
PROTO-ONCOGENE C-ERBB-1
Common Name English
Code System Code Type Description
FDA UNII
RO03J093CP
Created by admin on Tue Apr 01 16:34:18 GMT 2025 , Edited by admin on Tue Apr 01 16:34:18 GMT 2025
PRIMARY
UNIPROT
P00533
Created by admin on Tue Apr 01 16:34:18 GMT 2025 , Edited by admin on Tue Apr 01 16:34:18 GMT 2025
PRIMARY
From To
1_7 1_34
1_133 1_163
1_166 1_175
1_170 1_183
1_191 1_199
1_195 1_207
1_208 1_216
1_212 1_224
1_227 1_236
1_240 1_267
1_271 1_283
1_287 1_302
1_305 1_309
1_313 1_338
1_446 1_475
1_482 1_491
1_486 1_499
1_502 1_511
1_515 1_531
1_534 1_547
1_538 1_555
1_558 1_567
1_571 1_593
1_596 1_604
1_600 1_612
Glycosylation Link Type Site
N 1_32
N 1_49
N 1_104
N 1_151
N 1_172
N 1_328
N 1_337
N 1_389
N 1_420
N 1_504
N 1_544
N 1_579
N 1_599
Related Record Type Details
ZIRCONIUM PANITUMUMAB ZR-89
RADIOLIGAND->TARGET
Structure of (3R,4R)-4-AMINO-1-((4-((3-METHOXYPHENYL)AMINO)PYRROLO(2,1-F)(1,2,4)TRIAZIN-5-YL)METHYL)-3-PIPERIDINYL .BETA.-D-GLUCOPYRANOSIDURONIC ACID
INHIBITOR -> TARGET
IC50
Cetuximab
INHIBITOR -> TARGET
BINDING
Structure of WHI-P 154
INHIBITOR -> TARGET
Izalontamab
INHIBITOR -> TARGET
LAPRITUXIMAB EMTANSINE
CONJUGATED TOXIN->TARGET
Structure of NERATINIB DIMETHYLAMINE N-OXIDE
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
Structure of ABIVERTINIB
INHIBITOR -> TARGET
IC50
FUTUXIMAB
INHIBITOR -> TARGET
TOMUZOTUXIMAB
INHIBITOR -> TARGET
DULIGOTUZUMAB
INHIBITOR -> TARGET
Structure of CANERTINIB
INHIBITOR -> TARGET
ALLOGENEIC HUMAN AMNION/CHORION MEMBRANE
PARENT -> CONSTITUENT ALWAYS PRESENT
Structure of NRC-2694
INHIBITOR -> TARGET
In an in vitro study to test kinase selectivity profile of NRC-2694 (free base) against a panel of 353 kinases, NRC-2694 was found to be effective (0 or 0.1% of DMSO control) against EGFR, EGFR (E746-A750del), EGFR (G719C), EGFR (G719S), EGFR (L747-E749del, A750P), EGFR (L747-S752del, P753S), EGFR (L747-T751del, Sins), EGFR (L858R), EGFR (L861Q), EGFR (S752-I759del), GAK and LOK kinase.
IN-VITRO
AVID-100
CONJUGATED TOXIN->TARGET
Structure of N-DESMETHYL NERATINIB
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
AMIVANTAMAB
INHIBITOR -> TARGET
BINDING
SERCLUTAMAB
LIGAND->TARGET
Structure of PKI-166
INHIBITOR -> TARGET
Structure of 4,6-QUINAZOLINEDIAMINE, N4-(3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)-
INHIBITOR -> TARGET
IC50
Structure of ZORIFERTINIB
INHIBITOR -> TARGET
IC50
Structure of SPH-5030
INHIBITOR->OFF-TARGET
IC50
DEPATUXIZUMAB MAFODOTIN
LIGAND->TARGET
SERCLUTAMAB TALIRINE
CONJUGATED TOXIN->TARGET
Structure of ERLOTINIB
INHIBITOR -> TARGET
Structure of IBRUTINIB
INHIBITOR->OFF-TARGET
IC50
Structure of DOSIMERTINIB
INHIBITOR -> TARGET
IC50
Structure of AFATINIB
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
Structure of VARLITINIB
INHIBITOR -> TARGET
Structure of NERATINIB
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
Bafisontamab
INHIBITOR -> TARGET
MODOTUXIMAB
INHIBITOR -> TARGET
LAPRITUXIMAB
INHIBITOR -> TARGET
NIMOTUZUMAB
INHIBITOR -> TARGET
BINDING
PANITUMUMAB
INHIBITOR -> TARGET
BINDING
AVID-100
INHIBITOR -> TARGET
Izalontamab Brengitecan
INHIBITOR -> TARGET
Structure of Tigozertinib
WEAK INHIBITOR->TARGET
IC50
ABT-806I
INHIBITOR -> TARGET
Structure of Oritinib
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
IC50
Structure of Epertinib
INHIBITOR -> TARGET
IC50
Structure of (3R,4R)-4-AMINO-1-((4-((4-HYDROXY-3-METHOXYPHENYL)AMINO)PYRROLO(2,1-F)(1,2,4)TRIAZIN-5-YL)METHYL)-3-PIPERIDINOL
INHIBITOR -> TARGET
IC50
Structure of DACOMITINIB ANHYDROUS
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
Structure of XILIERTINIB
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
IC50
ANTI-EGFR MONOCLONAL ANTIBODY MIXTURE MM-151 ANTIBODY COMPONENT 3
INHIBITOR -> TARGET
LOSATUXIZUMAB VEDOTIN
CONJUGATED TOXIN->TARGET
DEPATUXIZUMAB
INHIBITOR -> TARGET
BINDING
Structure of 2-PROPENAMIDE, N-(4-((3-CHLORO-4-HYDROXYPHENYL)AMINO)-6-QUINAZOLINYL)-
INHIBITOR -> TARGET
IC50
Structure of PYROTINIB
INHIBITOR -> TARGET
IC50
Structure of SAPITINIB
INHIBITOR -> TARGET
Structure of AEE-788
INHIBITOR -> TARGET
Structure of BEFOTERTINIB
INHIBITOR -> TARGET
QRH-882260
LIGAND->TARGET
Structure of FALNIDAMOL
INHIBITOR -> TARGET
Structure of WSD-0922
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
Becotatug Vedotin
CONJUGATED TOXIN->TARGET
Structure of Lapatinib
INHIBITOR -> TARGET
Structure of BMS-690514
INHIBITOR -> TARGET
IC50
CETUXIMAB SAROTALOCAN
LIGAND->TARGET
IMAGING AGENT
Tilatamig
LIGAND->TARGET
DEPATUXIZUMAB MAFODOTIN
CONJUGATED TOXIN->TARGET
Structure of N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1H-pyrrolo[2,3-b]pyridin-1-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide
INHIBITOR -> TARGET
IN-VITRO
Structure of AV-412 FREE BASE
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
IC50
Structure of ASK-120067
INHIBITOR -> TARGET
IC50
Structure of EPITINIB
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
Emupertinib
INHIBITOR -> TARGET
NECITUMUMAB
INHIBITOR -> TARGET
Becotatug
INHIBITOR -> TARGET
Structure of Aumolertinib
INHIBITOR -> TARGET
Wild type receptor
IRREVERSIBLE INHIBITOR
IC50
Structure of POZIOTINIB
INHIBITOR -> TARGET
MATUZUMAB
INHIBITOR -> TARGET
BINDING
ZALUTUMUMAB
INHIBITOR -> TARGET
BINDING
Structure of VANDETANIB
INHIBITOR -> TARGET
ABT-806I
RADIOLIGAND->TARGET
Structure of ALLITINIB
INHIBITOR -> TARGET
irreversible selective inhibitor
IRREVERSIBLE INHIBITOR
IC50
Structure of NEPTINIB
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
DEMUPITAMAB
INHIBITOR -> TARGET
Structure of GEFITINIB
INHIBITOR -> TARGET
Structure of NERATINIB PYRIDINE N-OXIDE
INHIBITOR -> TARGET
IRREVERSIBLE INHIBITOR
Structure of N-(4-((3-CHLORO-4-((3-FLUOROPHENYL)METHOXY)PHENYL)AMINO)-6-QUINAZOLINYL)-2,3-DIHYDROXYPROPANAMIDE
INHIBITOR -> TARGET
IC50
TAK-186 activated dimer
INHIBITOR -> TARGET
Kills egfr expressing cells in tumor micfro
Structure of ERAS-801
INHIBITOR -> TARGET
PRECLINICAL
Structure of PELITINIB
INHIBITOR -> TARGET
Pamvatamig
INHIBITOR -> TARGET
IN-VIVO
LOSATUXIZUMAB
LIGAND->TARGET
Structure of Pebezertinib
INHIBITOR -> TARGET
PRECLINICAL
ETEVRITAMAB
LIGAND->TARGET
Structure of BRIGATINIB
INHIBITOR -> TARGET
Structure of SUTETINIB
INHIBITOR -> TARGET
IN-VITRO

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_974] [1_992] [1_1068] [1_1086] [1_1148] [1_1173] TYROSINE O-PHOSPHATE 2R86C98KDX
AMINO ACID SUBSTITUTION [1_654] THREONINE PHOSPHATE 3L4WX7B1EI
AMINO ACID SUBSTITUTION [1_1175] TILARGININE 27JT06E6GR
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966